[Immunological intervention to preserve beta-cell function in type 1 diabetes].
Type 1 diabetes is a chronic immune mediated disease leading to selective loss of insulin producing ss-cells. The incidence of type 1 diabetes has been rising. In past years quite a number of studies have been performed that aim to mitigate disease progression after diagnosis (tertiary prevention), in islet-antibody positive subjects at increased diabetes risk (secondary prevention) or in subjects genetically at risk but without autoantibodies (primary prevention). Studies of tertiary prevention are based on anti-inflammatory, T-cell directed, antigen-specific or stem cell approaches. Amelioration of disease course has been seen in a few of these trials, but no therapeutic regimen has so far been developed to cure type 1 diabetes after its clinical manifestation.
Schloot
N C
NC
Institut für Klinische Diabetologie am Deutschen Diabetes- Zentrum, Leibniz-Zentrum für Diabetesforschung an der Heinrich-Heine Universität, Düsseldorf, Germany. schloot@ddz.uni-duesseldorf.de
D001323:Autoantibodies / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D056747:Immunomodulation; D050417:Insulin-Secreting Cells / Q000276:immunology*
D001323:Autoantibodies; D007155:Immunologic Factors; C024211:islet cell antibody